

Sandhya Bangaru

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1434386/publications.pdf>

Version: 2024-02-01

19
papers

2,541
citations

516681

16
h-index

794568

19
g-index

28
all docs

28
docs citations

28
times ranked

5807
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020, 369, 643-650.	12.6	1,104
2	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. <i>Science</i> , 2020, 370, 1089-1094.	12.6	290
3	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. <i>Immunity</i> , 2020, 53, 1272-1280.e5.	14.3	185
4	A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. <i>Cell</i> , 2019, 177, 1136-1152.e18.	28.9	177
5	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. <i>Cell Reports</i> , 2020, 33, 108274.	6.4	152
6	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	12.4	79
7	A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. <i>Nature Communications</i> , 2018, 9, 2669.	12.8	67
8	H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. <i>Journal of Clinical Investigation</i> , 2016, 126, 1482-1494.	8.2	62
9	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <i>PLoS Pathogens</i> , 2020, 16, e1009089.	4.7	55
10	Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. <i>Cell Host and Microbe</i> , 2019, 26, 729-738.e4.	11.0	51
11	Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. <i>Cell Host and Microbe</i> , 2019, 26, 715-728.e8.	11.0	49
12	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021, 29, 806-818.e6.	11.0	49
13	Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. <i>PLoS Biology</i> , 2019, 17, e3000139.	5.6	37
14	Structure and immune recognition of the porcine epidemic diarrhea virus spike protein. <i>Structure</i> , 2021, 29, 385-392.e5.	3.3	37
15	Structural mapping of antibody landscapes to human betacoronavirus spike proteins. <i>Science Advances</i> , 2022, 8, eabn2911.	10.3	28
16	Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
17	Recognition of influenza H3N2 variant virus by human neutralizing antibodies. <i>JCI Insight</i> , 2016, 1, .	5.0	20
18	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner. <i>MBio</i> , 2021, 12, e0100221.	4.1	7

#	ARTICLE	IF	CITATIONS
19	Human antibody recognition of H7N9 influenza virus HA following natural infection. JCI Insight, 2021, 6, .	5.0	1